Sivilsamfunn i det globale Sør oppfordrer Norge å støtte patentunntak

Norge oppfordres å støtte et patentunntak i WTO under pandemien.

Over tohundre organsisasjoner i utviklingslandene ber statsminister Erna Solberg og den norske regjeringen om å støtte et patentunntak for vaksiner mot COVID-19 i WTO. Her kan du lese spørsmålet som ble sendt til Norge og svaret fra Statsministeren.

Organisasjonen Third World Network (TWN) har - på oppdrag av over tohundre frivillige organisasjoner og fagforeninger i utviklingslandene - sendt spørsmål til statsminister Erna Solberg om hvorfor Norge ikke støtter et patentunntak - det som blir kalt "TRIPS-Waiver-forslaget" - i Verdens handelsorganisasjon (WTO).

Handelskampanjen har tidligere spurt Utenriksministeren hvorfor Norge ikke støtter forslaget fra India og Sør Afrika om et unntak for patenter for vaksine mot COVID-19 under pandemien.

Norge stemte nei til forslaget om et patentunntak når det ble diskutert i TRIPS-rådet i WTO den 15. oktober og stemte også nei til en nærmere utredning av forslaget. På bakgrunn av dette sendte TWN følgende spørsmål til Statsministeren, 15. februar 2021:

Subject: Civil Society from Global South Calls for Support on COVID-19 TRIPS Waiver 

Honourable Prime Minister Erna Solberg,

The undersigned represent more than 200 non-governmental organizations and trade unions from developing countries struggling to secure COVID-19 vaccines as the pandemic devastates our communities and economies. We are writing to urge your government to withdraw its opposition and to support the proposal currently on the table at the World Trade Organization (WTO) to waive certain TRIPS1 obligations for the prevention, treatment, and containment of COVID-19.

The proposal was presented by India and South Africa on October 2, 2020. This proposal has gained the support and co-sponsorship of developing countries from around the world. The vast majority of developing countries as well as international organizations including the World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), UNITAID, and representatives of civil society, trade unions, human rights experts and academia have expressed their support for the proposed waiver.2

Since the start of the pandemic, Norway has expressed support for equitable and affordable access to all effective and safe vaccines, diagnostics, treatments, and other health technologies. And yet Norway continues to obstruct and oppose the waiver proposal, which seeks to remove relevant intellectual property monopolies so that production of COVID-19 medical products may be expanded and diversified globally.

More than a year into the pandemic, severe shortages of medical products including test kits, protective equipment, ventilators, therapeutics and medical devices persist in many countries, hampering prevention, treatment and containment of COVID-19.

The disparity in access to vaccines is especially shocking. High-income countries, which constitute just 16% of the world population have claimed 4.2 billion doses, compared to 2.5 billion doses by 84% of the world population. Many of these rich countries have purchased enough doses to vaccinate their population several times. According to WHO, more than three quarters of the vaccinations are in just 10 countries.3 The Africa Union Chair, President Cyril Ramaphosa of South Africa has pointed out the “painful irony” of clinical trials being conducted on the continent, which is now struggling to gain access to supply.

Global vaccine supply is presently dependent on a few pharmaceutical companies including Pfizer, AstraZeneca and Moderna, yet they are unable to meet global demand, even for rich countries. This situation is unsustainable and unacceptable. In a global health emergency in which substantial amounts of public funding have driven the research and development, it is simply unconscionable that these few pharmaceutical companies will benefit from their intellectual property monopolies while the world is suffering. We also stress that the COVAX facility will only make 2 billion doses available by the end of 2021, representing a mere fraction of the needs of 6.4 billion people in developing countries.

There is an urgent need to expand and diversify supply options and engage manufacturers from across the world in ramping up vaccine production. For this to happen, intellectual property barriers must be removed. The TRIPS Waiver is the best way to do this, allowing manufacturers and governments the freedom to act to meet the global need for COVID-19 vaccines and therapeutics.

Norway’s opposition to the adoption of the waiver is simply indefensible. It is contributing to deepening the global crises of inequality. This opposition is also “self-defeating”. The recent emergence of new variants has shown that so long as large parts of the world populations, especially vulnerable communities remain unprotected, new and more resistant virus mutations are likely to occur, threatening to prolong the pandemic, and continuing to further devastate livelihoods, communities and economies, worldwide, including in Norway.

The COVID-19 pandemic is more than a health crisis; it is an economic crisis, a humanitarian crisis, and a human rights crisis that requires compassion and global solidarity. We need urgent unprecedented action by world leaders to contain the virus globally. We need manufacturers from every continent, in developing countries, wherever possible, engaged in production, if we are to overcome this pandemic.

We strongly urge you to unconditionally support the proposal to waive certain TRIPS obligations for the prevention, treatment and containment of COVID-19 and to immediately stop obstructing its adoption.

We look forward to your support.

Sangeeta Shashikant, Third World Network
on behalf of the signatories

Third World Network

Les brevet med spørsmål i pdf her.


Svar fra statsminister Erna Solberg, 25. mars 2021:


Les svaret fra Statsministeren i pdf her.

Flere nyheter


Handelskampanjen c/o Utviklingsfondet
Mariboes Gate 8, 0183 Oslo

.(JavaScript must be enabled to view this email address)